中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(6): 1194-1198

Research advances in the application of liquid biopsy in the diagnosis and treatment of hepatocellular carcinoma

DOI: 10.12449/JCH250629

  • Department of Infectious Diseases，Research Laboratory of Clinical Virology，Ruijin Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200025，China

Research funding:

National Science and Technology Major Projects of the 13th Five-Year Plan (2018ZX10302204-001-003)

More Information
  • Corresponding author: ZHANG Xinxin， zhangx@shsmu.edu.cn （ORCID： 0000-0002-0598-6425）
  • Received Date: 2024-08-13
  • Accepted Date: 2024-12-10
  • Published Date: 2025-06-25
    Abstract
  • Hepatocellular carcinoma is one of the most common cancers， and due to the lack of obvious specific symptoms in its early stage， patients are often in the advanced stage at the time of diagnosis and tend to have a poor prognosis. Timely diagnosis and effective treatment in the early stage can help to prolong the survival time of patients. Liquid biopsy is a noninvasive technique that can obtain the information of tumor by detecting and analyzing related biomarkers， including circulating tumor cells， circulating tumor DNA， and extracellular vesicles， thereby contributing to early diagnosis， molecular pathological typing， and prognosis prediction. This article reviews the research advances in the application of liquid biopsy in the diagnosis and treatment of hepatocellular carcinoma.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68( 6): 394- 424. DOI: 10.3322/caac.21492.
    [2]
    MCGLYNN KA, PETRICK JL, EL-SERAG HB. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2021, 73( Suppl 1): 4- 13. DOI: 10.1002/hep.31288.
    [3]
    KULIK L, EL-SERAG HB. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156( 2): 477- 491. e 1. DOI: 10.1053/j.gastro.2018.08.065.
    [4]
    CHIDAMBARANATHAN-REGHUPATY S, FISHER PB, SARKAR D. Hepatocellular carcinoma(HCC): Epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1- 61. DOI: 10.1016/bs.acr.2020.10.001.
    [5]
    AHN JC, TENG PC, CHEN PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma[J]. Hepatology, 2021, 73( 1): 422- 436. DOI: 10.1002/hep.31165.
    [6]
    van de STOLPE A, PANTEL K, SLEIJFER S, et al. Circulating tumor cell isolation and diagnostics: Toward routine clinical use[J]. Cancer Res, 2011, 71( 18): 5955- 5960. DOI: 10.1158/0008-5472.CAN-11-1254.
    [7]
    LOW WS, WAN ABAS WA. Benchtop technologies for circulating tumor cells separation based on biophysical properties[J]. Biomed Res Int, 2015, 2015: 239362. DOI: 10.1155/2015/239362.
    [8]
    de BOER CJ, van KRIEKEN JH, JANSSEN-VAN RHIJN CM, et al. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver[J]. J Pathol, 1999, 188( 2): 201- 206. DOI: 3.0.CO;2-8">10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8.
    [9]
    HUANG XY, LI F, LI TT, et al. A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma[J]. J Nanobiotechnology, 2023, 21( 1): 25. DOI: 10.1186/s12951-023-01783-9.
    [10]
    LI W, LIU JB, HOU LK, et al. Liquid biopsy in lung cancer: Significance in diagnostics, prediction, and treatment monitoring[J]. Mol Cancer, 2022, 21( 1): 25. DOI: 10.1186/s12943-022-01505-z.
    [11]
    van der VAART M, PRETORIUS PJ. The origin of circulating free DNA[J]. Clin Chem, 2007, 53( 12): 2215. DOI: 10.1373/clinchem.2007.092734.
    [12]
    DIEHL F, SCHMIDT K, CHOTI MA, et al. Circulating mutant DNA to assess tumor dynamics[J]. Nat Med, 2008, 14( 9): 985- 990. DOI: 10.1038/nm.1789.
    [13]
    MARTIN-ALONSO C, TABRIZI S, XIONG K, et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies[J]. Science, 2024, 383( 6680): eadf2341. DOI: 10.1126/science.adf2341.
    [14]
    NIKANJAM M, KATO S, KURZROCK R. Liquid biopsy: Current technology and clinical applications[J]. J Hematol Oncol, 2022, 15( 1): 131. DOI: 10.1186/s13045-022-01351-y.
    [15]
    YE QW, LING SB, ZHENG SS, et al. Liquid biopsy in hepatocellular carcinoma: Circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18( 1): 114. DOI: 10.1186/s12943-019-1043-x.
    [16]
    GUO SY, HUANG J, LI GP, et al. The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis[J]. Mol Cancer, 2023, 22( 1): 193. DOI: 10.1186/s12943-023-01909-5.
    [17]
    von FELDEN J, GARCIA-LEZANA T, DOGRA N, et al. Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer[J]. Gut, 2021. DOI: 10.1136/gutjnl-2021-325036.[ Online ahead of print]
    [18]
    LEE YT, TRAN BV, WANG JJ, et al. The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma[J]. Cancers(Basel), 2021, 13( 12): 3076. DOI: 10.3390/cancers13123076.
    [19]
    YU D, LI YX, WANG MY, et al. Exosomes as a new frontier of cancer liquid biopsy[J]. Mol Cancer, 2022, 21( 1): 56. DOI: 10.1186/s12943-022-01509-9.
    [20]
    ZHU ZQ, HU EY, SHEN H, et al. The functional and clinical roles of liquid biopsy in patient-derived models[J]. J Hematol Oncol, 2023, 16( 1): 36. DOI: 10.1186/s13045-023-01433-5.
    [21]
    YU JJ, XIAO W, DONG SL, et al. Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma[J]. BMC Cancer, 2018, 18( 1): 835. DOI: 10.1186/s12885-018-4744-4.
    [22]
    KELLEY RK, MAGBANUA MJM, BUTLER TM, et al. Circulating tumor cells in hepatocellular carcinoma: A pilot study of detection, enumeration, and next-generation sequencing in cases and controls[J]. BMC Cancer, 2015, 15: 206. DOI: 10.1186/s12885-015-1195-z.
    [23]
    ZHAO LN, SONG JG, SUN YL, et al. Tumor-derived proliferative CTCs and CTC clusters predict aggressiveness and early recurrence in hepatocellular carcinoma patients[J]. Cancer Med, 2023, 12( 13): 13912- 13927. DOI: 10.1002/cam4.5946.
    [24]
    YEO W, WONG N, WONG WL, et al. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma[J]. Liver Int, 2005, 25( 2): 266- 272. DOI: 10.1111/j.1478-3231.2005.01084.x.
    [25]
    IIZUKA N, SAKAIDA I, MORIBE T, et al. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma[J]. Anticancer Res, 2006, 26( 6C): 4713- 4719.
    [26]
    CHEN K, ZHANG H, ZHANG LN, et al. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma[J]. World J Gastroenterol, 2013, 19( 20): 3143- 3149. DOI: 10.3748/wjg.v19.i20.3143.
    [27]
    ONO A, FUJIMOTO A, YAMAMOTO Y, et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy[J]. Cell Mol Gastroenterol Hepatol, 2015, 1( 5): 516- 534. DOI: 10.1016/j.jcmgh.2015.06.009.
    [28]
    ZHU GQ, LIU WR, TANG Z, et al. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: A prospective study[J]. Mol Oncol, 2022, 16( 2): 549- 561. DOI: 10.1002/1878-0261.13105.
    [29]
    LIAO WJ, YANG HY, XU HF, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing[J]. Oncotarget, 2016, 7( 26): 40481- 40490. DOI: 10.18632/oncotarget.9629.
    [30]
    SUN N, ZHANG C, LEE YT, et al. HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma[J]. Hepatology, 2023, 77( 3): 774- 788. DOI: 10.1002/hep.32692.
    [31]
    GOUDA MA, JANKU F, WAHIDA A, et al. Liquid biopsy response evaluation criteria in solid tumors(LB-RECIST)[J]. Ann Oncol, 2024, 35( 3): 267- 275. DOI: 10.1016/j.annonc.2023.12.007.
    [32]
    LI J, SHI LH, ZHANG XF, et al. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma[J]. Oncotarget, 2016, 7( 3): 2646- 2659. DOI: 10.18632/oncotarget.6104.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (621) PDF downloads(45) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return